Gert Van Assche

2001–2022 年に発表

160
論文数
53,301
被引用数
111
h 指数
160
i10 指数

被引用数

Gert Van Assche の年別被引用数1993 年: 被引用 1 件1994 年: 被引用 2 件2002 年: 被引用 3 件2003 年: 被引用 28 件2004 年: 被引用 71 件2005 年: 被引用 118 件2006 年: 被引用 161 件2007 年: 被引用 176 件2008 年: 被引用 197 件2009 年: 被引用 277 件2010 年: 被引用 357 件2011 年: 被引用 384 件2012 年: 被引用 399 件2013 年: 被引用 551 件2014 年: 被引用 623 件2015 年: 被引用 585 件2016 年: 被引用 598 件2017 年: 被引用 664 件2018 年: 被引用 642 件2019 年: 被引用 2,265 件2020 年: 被引用 2,307 件2021 年: 被引用 1,852 件2022 年: 被引用 1,376 件2023 年: 被引用 1,115 件2024 年: 被引用 1,558 件2025 年: 被引用 591 件2026 年: 被引用 11 件1995〜2001 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,235 件、この内訳の 18.8%イギリス: 引用元論文 1,311 件、この内訳の 7.6%中国: 引用元論文 1,227 件、この内訳の 7.1%イタリア: 引用元論文 1,179 件、この内訳の 6.9%カナダ: 引用元論文 1,063 件、この内訳の 6.2%フランス: 引用元論文 937 件、この内訳の 5.4%ドイツ: 引用元論文 851 件、この内訳の 4.9%オランダ: 引用元論文 741 件、この内訳の 4.3%ベルギー: 引用元論文 657 件、この内訳の 3.8%スペイン: 引用元論文 627 件、この内訳の 3.6%日本: 引用元論文 488 件、この内訳の 2.8%オーストラリア: 引用元論文 404 件、この内訳の 2.4%
0%18.8%その他 26.2%

分野

  • Biochemistry, Genetics and Molecular Biology58.9%
  • Medicine29.9%
  • Immunology and Microbiology6.3%
  • Neuroscience1.6%
  • Agricultural and Biological Sciences1%
  • Nursing0.5%
  • その他1.8%

トピック

  • Inflammatory Bowel Disease21.3%
  • Microscopic Colitis7.4%
  • Gut microbiota and health4%
  • Rheumatoid Arthritis Research and Therapies3.6%
  • Autoimmune and Inflammatory Disorders3.2%
  • Biosimilars and Bioanalytical Methods2.7%
  • その他57.8%

共著者

全論文

検索で開く
  1. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

    著者: , , , , , , , , , , , , , , , - New England Journal of Medicine 2013 被引用: 2,852

  2. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

    著者: , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 被引用: 1,180

  3. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD

    著者: , , , , , , , , , , , , - Gastrointestinal Endoscopy 2004 被引用: 1,774

  4. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Silvio Danese, Julián Panés, Guillaume Bouguen, Sarah O’Donnell, Benjamin Pariente, Shawn Winer, Stephen B. Hanauer, J -F Colombel - The American Journal of Gastroenterology 2015 被引用: 1,838

  5. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Crohn s and Colitis 2016 被引用: 2,071

  6. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial

    著者: , , , , , , , , , , , , , , , - The Lancet 2016 被引用: 1,064

  7. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease

    著者: , , , , , , , , , , , , , , , , , , , , , - Gastroenterology 2020 被引用: 317

  8. Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

    著者: , , , , , , , , , - Gastroenterology 2011 被引用: 1,258

  9. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn’s Disease

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , André D’Hoore, Danny De Looze, Filip Baert, Paul Pattyn, Philippe Zerbib, Frank Zerbib, S Viennot, Jean‐Louis Dupas, P Orsoni, Xavier Hébuterne, Amine Rahili, Matthieu Allez, Yves Panís, Max Reinshagen, Roland Scherer, Andreas Sturm, Wolfgang Kruis, Daniel-Simon Duek, Matti Waterman, Adi Lahat-Zok, Oded Zmora, Hagit Tulchinsky, Yair Edden, Antonino Spinelli, Vito Annese, Imerio Angriman, Gabriele Riegler, Francesco Selvaggi, Bas Oldenburg, Lennard P. L. Gilissen, G Montfort, Mark Löwenberg, Adrianus Willem Bemelman, Raúl Almenara, María Dolores Martín‐Arranz, Mariano García‐Arranz, Javier P. Gisbert, Rosana Palasí, Javier Pérez Gisbert, José Manuel Herrera Justiniano, Ricardo Rada, Ma Teresa Butrón, Ricardo Rada, Antonio López–Sanromán, Joaquín Hinojosa de Val, Amparo Solana, Xavier González-Argenté, C. Martínez Pastor, Héctor Guadalajara, C. Martínez Pastor, Héctor Guadalajara - Gastroenterology 2017 被引用: 485

  10. An expert consensus to standardise definitions, diagnosis and treatment targets for anti‐fibrotic stricture therapies in Crohn's disease

    著者: , , , , , , , , , , , , , , , , , , , , - Alimentary Pharmacology & Therapeutics 2018 被引用: 258

  11. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD

    著者: , , , , , , , , , , - Gut 2016 被引用: 413

  12. Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease

    著者: , , , , , , , , , , - Inflammatory Bowel Diseases 2017 被引用: 265

  13. Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alberto Signore, Damian Tolan, Jeroen A. W. Tielbeek, Dominik Weishaupt, Bart M. Wiarda, Andrea Laghi - Journal of Crohn s and Colitis 2013 被引用: 663

  14. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marc Lémann - The Lancet 2012 被引用: 642

  15. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

    著者: , , , , , , , , , , , , , , , , - Journal of Crohn s and Colitis 2012 被引用: 1,550

  16. Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

    著者: , , , , , , - New England Journal of Medicine 2003 被引用: 2,018

  17. Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

    著者: , , , , , , , , , - Gastroenterology 2015 被引用: 873

  18. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

    著者: , , , , , , , , , , , - Inflammatory Bowel Diseases 2012 被引用: 811

  19. Mucosal Gene Expression of Antimicrobial Peptides in Inflammatory Bowel Disease Before and After First Infliximab Treatment

    著者: , , , , , , , , , , , , - PLoS ONE 2009 被引用: 305

  20. Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease

    著者: , , , , , , , , , - Journal of Crohn s and Colitis 2015 被引用: 319

  21. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

    著者: , , , , , , , , , , , , , , , , , , , , , - The Lancet 2008 被引用: 1,238

  22. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis

    著者: , , , , , , , , , , , , - Journal of Crohn s and Colitis 2012 被引用: 889

  23. Treatment Algorithm for Mild and Moderate-to-Severe Ulcerative Colitis: An Update

    著者: , , , , , , , , - Digestion 2020 被引用: 141

  24. Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial

    著者: , , , , , , , , , , , , - Gastroenterology 2012 被引用: 581